Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genocea Biosciences Inc GNCAQ

Healthcare Biotechnology
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that... see more

Recent & Breaking News (GREY:GNCAQ)

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

GlobeNewswire May 24, 2022

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

GlobeNewswire April 28, 2022

Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

GlobeNewswire April 8, 2022

Genocea Biosciences to Host Investor Webinar

GlobeNewswire April 4, 2022

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

GlobeNewswire March 14, 2022

Genocea Provides Fourth Quarter 2021 Corporate Update

GlobeNewswire March 10, 2022

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

GlobeNewswire March 8, 2022

John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors

GlobeNewswire March 7, 2022

Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast

GlobeNewswire March 3, 2022

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 10, 2022

Genocea to Present at Upcoming Investor Conferences

GlobeNewswire January 5, 2022

Genocea Biosciences Provides Corporate Update

GlobeNewswire January 4, 2022

Genocea to Present at the Stifel 2021 Virtual Healthcare Conference

GlobeNewswire November 10, 2021

Genocea Provides Third Quarter 2021 Corporate Update

GlobeNewswire October 28, 2021

Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast

GlobeNewswire October 21, 2021

Genocea to Present at Upcoming Conferences

GlobeNewswire September 28, 2021

Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors

GlobeNewswire September 13, 2021

Genocea to Present at Upcoming Scientific and Investor Conferences

GlobeNewswire September 7, 2021

Genocea Provides Second Quarter 2021 Corporate Update

GlobeNewswire July 29, 2021

Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast

GlobeNewswire July 22, 2021